AI-Driven Genomics Company Uses Investment to Fuel Commercial Expansion
Genomenon’s AI-driven Genomic Landscapes are used by top 100 pharma and biopharma companies to gain a profound understanding of the genetic drivers and clinical attributes of any genetic disease, from rare diseases to cancer. These datasets enable Pharma to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval.
A comprehensive understanding of Genomics is essential to advancing Precision Medicine, and Genomenon uniquely meets that need in ways that have led to quick adoption in the market. The company’s freemium model makes the Mastermind Genomic Search Engine freely available to a broad range of scientists, academics, and clinicians, and their user base of well over ten thousand extends to more than 118 countries. The company also offers a paid version of Mastermind to further accelerate genetic interpretation and patient diagnosis.
New investors in this round of financing included BroadOak Capital Partners, Green Park & Golf Ventures, Red Cedar Ventures and Michigan Rise with continued support from existing investors Invest Detroit Ventures, IrishAngels, Michigan Angel Fund, Invest Michigan and Atain Specialty Insurance Company.
Skip Simms, Managing Member of Michigan Angel Fund, said of Genomenon “This is a well-run company and world class team of people driving this game-changing technology and service. They build shareholder value every week and we’re delighted to be one of those major shareholders.”
Lauren Tyra, Chief Scientific Officer of Green Park & Golf Ventures, said, “We are excited to be supporters of Genomenon’s forward-looking approach to genetic and rare disease diagnosis. Better and more comprehensive tools are clearly needed in this space to get patients properly diagnosed and on treatment more quickly, and we are thrilled Genomenon is part of that next generation of tools. The ability to match the right patients with next-generation targeted therapeutics quickly and at scale is a significant advantage to current approaches.”
About Genomenon
Genomenon is an AI-driven genomics company that organizes the world's genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.
Genomenon was named Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.